---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-005618"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:31:00.183921+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arbutus to present imdusiran Phase 2a data in 4 posters at AASLD, including 2 late-breakers

## Summary
- Four poster presentations at AASLD 2024 (Nov 15-19, San Diego) feature imdusiran, an RNAi therapeutic for chronic HBV.
- Late-breaking posters will show IM-PROVE I and IM-PROVE II Phase 2a trial data.
- Immune biomarker profiling in subjects treated with imdusiran + pegylated interferon reveals phases of immune activation linked to HBsAg seroconversion.
- Imdusiran target site is highly conserved across HBV genotypes A-E; SNPs do not affect HBsAg decline.
- Posters will be available on Arbutus website from November 15, 2024.

## SEC filing metadata
- accession: 0001171843-24-005618
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324005618/0001171843-24-005618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324005618/f8k_101524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-005618
- JSON: https://secwatch.observer/filing/0001171843-24-005618.json
- Plain text: https://secwatch.observer/filing/0001171843-24-005618.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.